# Sharon Rosenzweig-Lipson **Entity class:** Person **Domain:** cellular rejuvenation / ophthalmology / regenerative medicine **Maturity:** Developing ## Significance Sharon Rosenzweig-Lipson is Chief Scientific Officer of Life Biosciences. Her work represented here concerns the first human clinical development of ER-100, an epigenetic-restoration therapy testing whether damaged retinal ganglion cells can be returned toward a younger functional state. ## Relationships - [[wiki/Age Reversal|Age Reversal]] - [[wiki/Regenerative Medicine|Regenerative Medicine]] - [[wiki/Longevity Escape Velocity|Longevity Escape Velocity]] ## Source Dossiers - [[research/Weekly Reminder Hunt - 2026-10-02|Weekly Reminder Hunt — October 2, 2026]] ## Simple Reminders, Quotations, and Thoughts > "People living with age-related vision loss like the two optic neuropathies we are currently focused on, open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION), have no therapeutic options that address the underlying damage to retinal ganglion cells. With ER-100, we are testing whether we can restore these cells to a more youthful state, not just slowing vision loss but potentially reversing it." > **— Sharon Rosenzweig-Lipson**, *Life Biosciences to Present First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies at Eyecelerator 2026, October 1, 2026* [[reminders/Regenerative Medicine/Cellular Rejuvenation May Reverse Age-Related Vision Loss by Sharon Rosenzweig-Lipson|Cellular Rejuvenation May Reverse Age-Related Vision Loss by Sharon Rosenzweig-Lipson]]